**Reviewer’s report**

**Title:** Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS)

**Version:** 0  **Date:** 18 Oct 2017

**Reviewer:** Andrzej Plawski

**Reviewer's report:**

The authors tried to find the molecular changes leading to initiation and/or development of cancer in the case of serrated polyps. Serrated polyps are rare colorectal lesions. The sequence of molecular alteration involved in a serrated polyp-CRC sequence still need the be defined.

Authors used modern methods of molecular biology to find such alteration in their material.

They had few serrated polyps from one patient. They conducted deep molecular analysis of their material. I have no objections considering the way of the studies conducting. Authors have a unique material and the postulate that the epigenetic changes may be important factor in serrated polyps development. My question is why they did not check it. In my opinion the studies were conducted properly, conclusions are correct. However there is not is no breakthrough in the identification of pathway of the serrated polyps development.

**Level of interest**

Please indicate how interesting you found the manuscript:

An article of importance in its field

**Quality of written English**

Please indicate the quality of language in the manuscript:

Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal